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Research
It is increasingly clear that adverse events 
during fetal development contribute to sub-
sequent morbidity in adulthood. Although 
Barker (2003) originally showed that intra-
uterine stress sufficient to cause growth 
retardation contributed substantial risk to 
subsequent development of cardio  vascular 
disease and diabetes, more recent results sug-
gest that environmental contaminants, drugs, 
and chemicals can produce similar adverse 
outcomes, without growth restriction. We 
and others have been exploring how expo-
sures to common pesticides might provide a 
route to later-emerging disorders, in particu-
lar focusing on organophosphorus pesticides 
(OPs), which represent 50% of worldwide 
insecticide use (Casida and Quistad 2004). 
Because pregnant women are typically 
exposed to OPs under circumstances that 
do not elicit outward signs of intoxication, 
and in light of recent findings suggesting that 
such exposures can produce long-term neuro-
behavioral deficits in children (Eskenazi et al. 
2008; Rauh et al. 2006; Rosas and Eskenazi 
2008), the mechanisms and consequences 
of apparently subtoxic OP exposures remain 
major environ  mental concerns.
Although the systemic toxicity and signs 
of OP intoxication reflect their shared abil-
ity to inhibit cholinesterase (Mileson et al. 
1998), recent data indicate that lower-level 
OP exposures disrupt cell-signaling cas-
cades that control cell differentiation and 
other critical regulatory functions (Slotkin 
2005). Chief among these is the pathway that 
generates cyclic AMP (cAMP). This criti-
cal second messenger is controlled through 
neuro  transmitter and hormonal receptors that 
link through G-proteins to regulate adeny-
lyl cyclase (AC), the enzyme that synthesizes 
cAMP from ATP. Chlorpyrifos (CPF), the 
most studied OP, targets the AC cascade at 
multiple points, including the number and 
activity of G-protein–coupled receptors, the 
concentration and function of the G-proteins, 
and the expression and catalytic activity of 
AC itself (Curtin et al. 2006; Huff et al. 
2001; Meyer et al. 2004; Song et al. 1997). 
However, AC signaling is critically important 
in the development and function of cells and 
organs besides the central nervous system and 
is notably involved in the control of meta-
bolic and cardio  vascular processes. Indeed, 
we showed that neonatal CPF exposure dys-
regulates hepatic and cardiac AC (Meyer et al. 
2004), with global sensitization of hepatic 
AC, augmenting the responses to multiple 
neuro  humoral inputs and leading ultimately 
to metabolic abnormalities resembling those 
in prediabetes (Slotkin et al. 2005). 
Because OP effects on cell signaling do 
not necessarily involve their shared property 
as cholinesterase inhibitors, there is no rea-
son to presuppose that all OPs will act in the 
same way. Indeed, neonatal exposure to para-
thion (PRT) also elicits metabolic changes 
related to pre  diabetes (Lassiter et al. 2008), 
but the specific defects differ from those seen 
with comparable exposure to CPF (Slotkin 
et al. 2005); further, patterns of weight gain 
and loss after neonatal exposure to diazinon 
(DZN) also diverge from those evoked by 
CPF or PRT (Lassiter and Brimijoin 2008; 
Lassiter et al. 2008; Roegge et al. 2008). 
Accordingly, in the present study, we exam-
ined whether the diverse outcomes of early-
life exposure to different OPs are associated 
with differences in their long-term effects 
on AC signaling. We evaluated function at 
each step in the cascade in liver and heart [see 
schematic in Supplemental Material, avail-
able online (doi:10.1289/ehp.0901237.S1 via 
http://dx.doi.org/)] after neonatal exposure 
to DZN and PRT over periods ranging from 
early adolescence [post  natal day 30 (PND30)] 
through young adulthood (PND60) and late 
adulthood (PND100). In addition to assess-
ing the effects on basal AC activity, we evalu-
ated the response to β-adrenergic receptors 
(βARs) and glucagon receptors, both of which 
stimu  late AC via activation of the stimulatory 
G-protein (Gs). We also determined the effect 
of fluoride, which evokes maximal activation 
of both Gs and the corresponding inhibitory 
protein (Gi). We then measured the maximal 
activation of AC itself by forskolin, which 
acts directly on the enzyme by binding to 
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the catalytic core (Hurley 1999). Further, we 
meas  ured ligand binding for βARs and for the 
inhibitory m2-muscarinic acetylcholine recep-
tors (m2AChRs). We compared the effects of 
each OP on the trajectory of development of 
hepatic and cardiac AC signaling with those 
in the cerebellum, a brain region that shares 
the same high degree of AC response to βAR 
stimulation (Slotkin et al. 1998).
Materials and Methods
Animal treatments. All experiments were car-
ried out humanely and with regard for alle-
viation of suffering, with protocols approved 
by the Institutional Animal Care and Use 
Committee and in accordance with all fed-
eral and state guidelines. Timed-pregnant 
Sprague-Dawley rats (Charles River, Raleigh, 
NC) were housed in breeding cages, with a 
12/12-hr light/dark cycle and free access to 
food and water. On the day of birth, all pups 
were randomized and redistributed to the 
dams with a litter size of 10 to maintain a 
standard nutritional status. Randomization 
within their respective treatment groups was 
repeated at intervals of several days. In addi-
tion, dams were rotated among litters to dis-
tribute any maternal caretaking differences 
randomly across litters and treatment groups. 
Offspring were weaned on PND21. Because 
of their poor water solubility, DZN and PRT 
(Chem Service, West Chester, PA) were dis-
solved in dimethyl sulfoxide (DMSO) to 
provide consistent absorption (Whitney et al. 
1995) and were injected subcutaneously in a 
volume of 1 mL/kg once daily on PNDs 1–4. 
Control animals received equivalent injections 
of DMSO vehicle, which does not itself pro-
duce develop  mental toxicity (Song et al. 1997; 
Whitney et al. 1995). At PND30, PND60, 
and PND100, one male and one female from 
each final litter assignment were weighed and 
decapitated, and the heart, one liver lobe, and 
the cerebellum were dissected, blotted, frozen 
in liquid nitrogen, and maintained at –45°C. 
Other tissues and brain regions were reserved 
for future studies. The animals used here were 
part of a much larger cohort used in our previ-
ous studies with DZN and PRT (Lassiter et al. 
2008, 2010; Roegge et al. 2008; Timofeeva 
et al. 2008a, 2008b).
The dosing paradigms were chosen to 
achieve a toxico  dynamic match between DZN 
and PRT (Slotkin et al. 2006a, 2006b) and, 
similarly, to match earlier studies using CPF 
(Song et al. 1997). For each OP, we chose 
doses that are toxico  dynamically equivalent, as 
assessed through measurements of brain cho-
linesterase inhibition: 0.5 and 2 mg/kg/day for 
DZN, and 0.1 and 0.2 mg/kg/day for PRT. 
Assays. All procedures and materials used 
in this study were previously presented in 
detail (Meyer et al. 2004) and are described 
briefly here. Cell membrane preparations 
were assayed for AC activity in a two-step 
procedure, with an enzymatic step generating 
cAMP and subsequent analysis using com-
mercial kits. In addition to assessing basal AC 
activity, we evaluated responses to 100 µM 
isoproterenol, 3 µM glucagon, 10 mM 
sodium fluoride, and 100 µM forskolin, con-
centrations shown in our earlier work to be 
maximally effective for AC stimulation. βAR 
binding was assayed in the same membrane 
preparation, using 67 pM [125I]iodopindolol 
as the radio  ligand and 100 µM isoproterenol 
to displace specific binding. For m2AChR 
binding, we used 1 nM [3H]AFDX384, with 
or without 1 µM atropine. For the ligand 
binding determinations, technical limitations 
were imposed by the large number of mem-
brane preparations that had to be examined. 
The overall strategy was to determine binding 
at a single subsaturating ligand concentration 
to enable the detection of changes that origi-
nate in alterations of either Kd (dissociation 
constant) or Bmax (maximum binding). 
Data analysis. Data are presented as 
means ± SEs obtained from six animals in 
each treatment group for each sex and age 
point. To establish treatment differences, we 
first conducted a global analysis of variance 
(ANOVA; data log-transformed because of 
hetero  geneous variance across ages, tissues, 
and AC stimulant) for all variables: the in vivo 
treatment groups (control vs. low and high 
OP doses), which OP was given (DZN vs. 
PRT), age, sex, tissue, and the stimulant con-
dition (repeated measure). As justified by sig-
nificant interactions of treatment with the 
other variables, data were then subdivided 
into lower-order ANOVAs, followed, where 
appropriate, by Fisher’s protected least sig-
nificant difference test to identify individual 
values for which the OP groups differed from 
the control. Significance for main treatment 
effects was assumed at p < 0.05. However, 
for interactions at p < 0.1, we also exam-
ined whether lower-order main effects were 
detectable after subdivision of the interactive 
variables (Snedecor and Cochran 1967). The 
criterion for interaction terms was used not 
to assign significance but rather to identify 
inter  active variables requiring subdivision for 
lower-order tests. Where treatment effects 
were not interactive with other variables, we 
report only the main treatment effects with-
out performing lower-order analyses.
To enable ready visualization of treat-
ment effects across different tissues, ages, and 
stimulants, the results are given as the per-
cent change from control values, but statis-
tical procedures were always conducted on 
the original data. Control values are shown 
in the Supplemental Material, Table 1, 
(doi:10.1289/ehp.0901237.S1)], which also 
shows the highly significant increase in AC 
evoked by each of the stimulants.
Results
Multivariate ANOVA incorporating all age 
points and both sexes showed that neonatal 
OP exposure elicited small but statistically sig-
nificant effects on body weight (main treatment 
effect, p < 0.004) and heart weight (p < 0.0001); 
liver weights could not be compared because we 
dissected only a single lobe. The effects on body 
and heart weight depended on which OP was 
given, as evidenced by significant interactions 
of treatment × (DZN vs. PRT): p < 0.02 for 
body weight, p < 0.005 for heart weight. DZN 
produced a significant overall reduction in 
body weight at either 0.5 or 2 mg/kg, amount-
ing to net deficits of 5% (p < 0.003) and 6% 
(p < 0.0006), respectively (data not shown), 
consistent with earlier findings (Roegge et al. 
2008); for heart weight, the reductions were 
slightly larger, 8–9% (p < 0.0001 for either 
dose). In contrast, for PRT we found no sta-
tistically significant effects on body or heart 
weights in the animals used for this study (data 
not shown); however, these animals were part 
of a much larger cohort that was used for addi-
tional studies (Lassiter et al. 2008; Slotkin et al. 
2009), and in the overall group, PRT caused a 
small (2–3%) but significant elevation in body 
weight at the low dose in males and reductions 
of about 4% at either dose in females.
Global ANOVA for AC measurements 
indicated a significant main effect of OP treat-
ment reflecting overall increases in activity 
(p < 0.0001; OP treated > control) that dif-
fered between liver and heart (treatment ×   
tissue, p < 0.0001) and between DZN and 
PRT [treatment × (DZN vs. PRT), p < 0.04], 
as well as displaying more complex inter-
actions: p < 0.004 for treatment × (DZN vs. 
PRT) × age; p < 0.02 for treatment × (DZN vs. 
PRT) × age × tissue; p < 0.0001 for treatment 
× AC stimulant; and p < 0.0001 for treatment 
× tissue × AC stimulant. Accordingly, for pre-
sentation we separated the data into the indi-
vidual tissues (liver, heart, cerebellum) and 
treatments (DZN, PRT) and then performed 
lower-order tests to reexamine the results for 
treatment effects and interactions.
Liver AC. In the liver, neonatal OP expo-
sure elicited a significant main treatment effect 
(p < 0.0001) that differed between the two 
OPs and among ages [treatment × (DZN vs. 
PRT), p < 0.08; treatment × (DZN vs. PRT) 
× age, p < 0.0001] and also showed selectivity 
among the various AC stimulants (treatment 
× AC stimulant, p < 0.0001). Accordingly, 
we separated the results for DZN and PRT 
for each age point and then reexamined the 
  treatment effects.
DZN exposure elicited a significant main 
treatment effect (p < 0.0001), reflecting an 
overall gain of function, with dependence 
on age (treatment × age, p < 0.08) and AC 
stimulant (treatment × stimulant, p < 0.005). 
On PND30 we observed a trend toward Adigun et al.
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overall increases in AC activity in males that 
did not by itself achieve statistical significance 
(Figure 1A); however, we saw the same pattern 
in the heart, and the overall effect across both 
tissues was significant. By young adulthood 
(PND60), the main effect of DZN treatment 
became significant for both sexes, reflecting a 
robust enhancement of activity in the animals   
exposed to 2 mg/kg (Figure 1B). Superimposed 
on this general increase, there were selectively 
greater effects on responses to stimulants acting 
through Gs-coupled receptors (isoproterenol, 
glucagon) than on the response to fluoride, 
which stimulates both Gs and Gi; the response 
to forskolin was also increased to a greater 
extent than that to fluoride. By PND100 
(Figure 1C), both the low and high doses of 
DZN elicited significant increases in AC. Like 
the PND60 values, the fluoride response was 
affected to a lesser extent than that to the recep-
tor stimulants or forskolin (p < 0.002 for treat-
ment × stimulant across the two age points).
For hepatic effects of PRT exposure, the 
global ANOVA indicated a significant main 
Figure 1. Effects of neonatal exposure to DZN (A–C) or PRT (D–F) on liver AC activity on PND30 (A, D), PND60 (B, E), and PND100 (C, F). Abbreviations: Fsk, for-
skolin; Glu, glucagon; Iso, isoproterenol; NaF, sodium fluoride; NS, not significant. ANOVA incorporating the factors of treatment, sex, and AC stimulant appears 
at the top of each panel, and lower-order tests are shown within the panels. Where there was a significant treatment × stimulant interaction, asterisks denote 
specific responses that differ from the control animals (males and females combined); separate tests for males and females were not carried out because of the 
absence of treatment × sex interactions. 
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Figure 2. Effects of neonatal exposure to DZN (A–C) or PRT (D–F) on heart AC activity on PND30 (A, D), PND60 (B, E), and PND100 (C, F). Abbreviations: Fsk, for-
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treatment effect (p < 0.0009) that depended 
on age (treatment × age, p < 0.003), AC stimu-
lant (treatment × stimulant, p < 0.0001), and 
sex (treatment × stimulant × sex, p < 0.06). 
Most notably, the temporal pattern of effects 
was completely distinct from that of DZN. 
On PND30 (Figure 1D), neonatal PRT expo-
sure elicited significant up-regulation of AC 
activity at both 0.1 mg/kg and 0.2 mg/kg. 
Superimposed on the overall increase, the 
lower dose elicited selectively greater effects on 
the responses to isoproterenol and forskolin 
than on those to glucagon or fluoride; we saw 
the same pattern at the higher dose, although 
the greater overall effect increased the response 
sufficiently to achieve statistical significance 
for all the individual measures. On PND60, 
the point at which DZN elicited even greater 
increases in hepatic AC activity, PRT instead 
showed a loss of effect (Figure 1E), and the 
same was true in full adulthood, by PND100 
(Figure 1F). To make certain that later- 
emerging changes were not occurring with 
PRT exposure, we performed an additional 
set of determinations at 5 months of age and 
again found no persistent overall effects on AC 
(data not shown).
Heart AC. In the heart, the effects of neo-
natal toxicant exposure were less statistically 
robust than for the liver, but we nevertheless 
found differences between the two OPs [treat-
ment × (DZN vs. PRT), p < 0.07], as well 
as treatment interactions with age and AC 
stimulant (treatment × age × AC stimulant, 
p < 0.04). Again, values were separated into the 
individual treatments and ages for comparisons 
of lower-order treatment effects. On PND30 
(Figure 2A), DZN treatment enhanced AC 
activity in a sex- and stimulant-selective man-
ner. At the lower dose, we observed small 
overall effects that achieved statistical signifi-
cance for 2 of the 12 parameters. More robust 
effects were evident at the higher dose, reflect-
ing a net overall increase in males; in females, 
the responses to isoproterenol and glucagon 
were decreased by DZN exposure, whereas 
the response to fluoride was unchanged and 
that to forskolin was increased. The augmented 
responses seen in males were similar in direc-
tion and magnitude to those noted for the 
liver at the same age (Figure 1A); ANOVA 
incorporating both tissues confirmed a main 
effect of DZN treatment (p < 0.008) without 
tissue selectivity (no treatment × tissue inter-
action). By PND60, we no longer detected 
significant effects of DZN on heart AC activity 
(Figure 2B), although a slight enhancement 
reappeared by PND100 that did not achieve 
statistical significance (Figure 2C).
In contrast to the effect of DZN on heart 
AC, we did not detect significant effects of 
PRT on the same parameters (Figure 2D–F). 
Again, we performed a follow-up study at 
5 months of age to determine if alterations 
might emerge even later on but found no sig-
nificant treatment effects (data not shown).
Receptors. For βARs, global ANOVA 
identified interactions of treatment × age 
(p < 0.004), treatment × sex (p < 0.05), treat-
ment × tissue (p < 0.09), treatment × (DZN vs. 
PRT) × sex (p < 0.01), treatment × (DZN vs. 
PRT) × tissue (p < 0.1), and treatment × (DZN 
vs. PRT) × tissue × age (p < 0.08). Again, we 
separated the values for the DZN and PRT 
treatments and examined lower-order main 
treatment effects and interactions of treatment 
with other variables. For DZN (Figure 3A), 
we found treatment interactions with sex and 
tissue. Separation of the values by tissue did not 
reveal any individually significant treatment 
effects. However, separation by sex confirmed 
an overall significant reduction in βAR bind-
ing in females exposed to the lower dose of 
DZN; this effect had a magnitude of < 10%, 
far smaller than the 30–40% changes seen for 
the AC response to βAR stimulation, and was 
in the opposite direction (decrease for βARs, 
increase for AC response). Neonatal PRT 
treatment also evoked significant changes in 
βAR binding that depended on age and tis-
sue (Figure 3B). Separate analyses for each tis-
sue indicated an age-dependent effect in the 
liver, reflecting an increase on PND30 and a 
decrease on PND60, restricted to the high-dose 
group. In the heart, βAR binding was decreased 
  selectively in males.
We evaluated m2AChR binding only in 
the heart because these receptors are sparse in 
the liver and cerebellum. The global ANOVA 
identified a treatment × sex interaction, and 
subdivision of the results showed a significant 
treatment effect in females. Nevertheless, the 
net effect was quite small, and the only deter-
minations that achieved statistical significance 
were those for 0.5 mg/kg DZN (Figure 3C).
Cerebellum. Neonatal exposure to 
the lower dose of DZN elicited significant 
increases in cerebellum AC activity that were 
selective for males, but the higher dose instead 
produced small but significant decrements 
(Figure 4); the magnitude of the effects was 
substantially smaller than that seen in the 
liver at the same age (PND100). The low dose 
of PRT did not elicit significant alterations 
in cerebellar AC parameters, but the high 
dose produced an overall increase without sex 
selectivity. None of the treatments had a sig-
nificant effect on cerebellar βAR binding.
Figure 3. Effects of neonatal DZN or PRT exposure on liver and heart receptors. (A) βAR binding in DZN-exposed animals. (B) βAR binding in PRT-exposed animals. 
(C) Cardiac m2AChR binding in animals exposed to DZN or PRT. ANOVA incorporating the factors of treatment, sex, age, and tissue appears at the top of each panel, and 
lower-order tests are shown within the panels. Asterisks in (B), where there was a treatment × age interaction, show ages for which the PRT group differs from the control.
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Figure 4. Effects of neonatal exposure to DZN (top) 
or PRT (bottom) on the cerebellum, evaluated at 
PND100. Abbreviations: Fsk, forskolin; Iso, isoprot-
erenol; NaF, sodium fluoride. Multivariate ANOVA 
appears at the top of the panel, and lower-order 
tests are shown within the panels. 
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Discussion
Results of this study reinforce the concept 
that the developmental effects of OPs extend 
beyond the nervous system. Neonatal expo-
sures to DZN and PRT altered the develop-
mental trajectory of AC-mediated cell signaling 
in peripheral tissues, and to a greater extent in 
the liver than in the cerebellum. Although, in 
general, OP exposure elicited a net AC gain-of-
function, the effects differed among the various 
tissues, effectively ruling out a global effect on 
expression of receptors, G-proteins, or AC and 
instead pointing to selectively greater effects 
on specific aspects of hepatic function. This 
conclusion was further reinforced by the fact 
that DZN and PRT exposures evoked different 
trajectories despite doses of each OP chosen to 
be toxicodynamically equivalent (Slotkin et al. 
2006b): The effects of DZN intensified with 
age, whereas those of PRT waned.
In our previous work with CPF, we found 
persistent, global increases in all measures 
of hepatic AC signaling, an effect restricted 
to males (Meyer et al. 2004); this connotes 
global sensitization of the pathway, wherein 
up-regulation of AC activity itself (enhanced 
forskolin response) produces an augmented 
response to stimulants acting on Gs-coupled 
receptors (isoproterenol, glucagon), as well as 
to those directly activating G-proteins (fluo-
ride). Equally important, the CPF effects dis-
played a critical period of sensitivity, indicating 
that these are specifically develop  mental actions 
(Meyer et al. 2004). As found in the present 
study, neonatal DZN exposure produced a 
similar global effect that appeared in adoles-
cence and young adulthood at the higher dose 
but that also became significant at the lower 
dose by full adulthood; notably, although 
the effect emerged first in males, it eventually 
encompassed both sexes, thus differing in out-
come from the sex-specific effects seen for CPF 
(Meyer et al. 2004). We also found alterations 
in specific elements of the signaling cascade 
superimposed on global sensitization. If the 
up-regulation of AC itself were the only effect 
of DZN exposure, then all pathway stimulants 
should show the same degree of enhancement. 
Instead, at both PND60 and PND100, the 
response to fluoride was augmented to a sig-
nificantly smaller extent than that for forskolin 
or either of the receptor stimulants. Fluoride 
differs from isoproterenol and glucagon in 
that it also activates Gi, and consequently, 
our findings point to an increase in expres-
sion and/or function of Gi after neo  natal DZN 
exposure; again, this differs from the effects 
of CPF, which produces uniform enhance-
ment of responses as expected from activation 
of AC itself (Meyer et al. 2004). Effects on 
Gi will also produce global alterations in AC 
signaling because they affect the response to 
any receptor acting through Gi. Thus, all the 
effects we noted involved the signaling proteins 
downstream from the receptors, either AC itself 
or the G-proteins, rather than reflecting effects 
on the expression of the neuro  transmitter 
receptors or their specific coupling to the con-
trol of AC. Indeed, none of the small effects 
seen for receptor binding could account for the 
robust augmentation of AC responses.
In contrast to DZN, neonatal PRT expo-
sure produced a much larger initial sensiti-
zation of hepatic AC in adolescence, again 
involving global changes at the level of AC 
itself, but additional pathway effects were 
evident at the lower dose, reflecting smaller 
increments for glucagon and fluoride than 
for isoproterenol and forskolin. In turn, these 
effects imply homologous desensitization 
for glucagon and heterologous increases in 
Gi-mediated inhibition; the effect of PRT on 
the glucagon response was not shared by DZN, 
again pointing out specific differences related 
to each individual OP. Further, the effects of 
DZN intensified over time, whereas those of 
PRT waned. Thus, the two OPs differ com-
pletely in their effects on the develop  mental 
trajectory of hepatic AC signaling, with large 
effects in adolescence for PRT but not DZN, 
supplanted by the opposite pattern in adult-
hood. The fact that AC signaling in the liver 
was affected far more than in either the heart 
or cerebellum further demon  strates selective 
effects of early-life OP exposure. Finally, for 
the heart (but not the cerebellum), we found 
significant changes in receptor binding with-
out apparent connection to the effects on AC 
signaling, again reinforcing the importance of 
sensitization downstream from the receptors as 
the primary site of regulatory disruption.
The clear implication is that neonatal OP 
exposure is likely to affect hepatic responses to 
a greater extent than those in the heart or in 
the central nervous system, and it is therefore 
critical to examine how the cellular changes 
seen here might then contribute to alterations 
in tissue function. In the liver, where βARs 
and glucagon receptors are linked through 
AC to enhanced gluco  neo  genesis and lipoly-
sis, global sensitization of AC signaling leads 
to corresponding metabolic abnormalities. In 
our earlier work with CPF, we established the 
presence of hyperlipidemia, but serum glucose 
levels were maintained within normal limits 
(Slotkin et al. 2005); however, glucose homeo-
stasis was maintained only by compensatory 
hyper  secretion of insulin, thus producing a 
metabolic profile akin to prediabetes. Critical 
to the proposed mechanistic connections, the 
sex selectivity of the metabolic effects (males) 
exactly matched that for the sensitization of 
hepatic AC signaling (Meyer et al. 2004). 
More recently, we also found evidence of pre-
diabetes after neonatal PRT exposure (Lassiter 
et al. 2008). In this case, there was no cor-
responding increase in serum insulin, and as a 
result, the animals displayed a frank prediabetic 
profile, characterized by hyperglycemia and 
impaired glucose and lipid utilization (Lassiter 
et al. 2008). It is thus important to note that 
the effects of PRT on hepatic AC signaling 
seen here were restricted to adolescence and, 
unlike those of CPF, did not persist into adult-
hood. Accordingly, for PRT, either the AC 
changes are unrelated to the metabolic disor-
ders, or the effects in adolescence may be suf-
ficient to reprogram metabolism so that defects 
emerge later, despite the sub  sequent normal-
ization of signaling parameters. Future work 
will need to dissect the temporal emergence 
of prediabetes after neonatal PRT exposure 
in order to distinguish these two possibilities. 
However, the present data point toward the 
latter interpretation, because PRT-exposed 
animals show a switch from enhanced to sup-
pressed weight gain coinciding with the time 
course for the disappearance of the effects on 
AC signaling (Lassiter et al. 2008). Although 
detailed metabolic studies have not been done 
for DZN, based on the results for hepatic AC 
signaling, we would expect to see greater meta-
bolic defects than for PRT, consistent with the 
greater weight loss seen here and in earlier stud-
ies (Lassiter et al. 2008; Roegge et al. 2008); 
we further predict that, unlike CPF, DZN 
will target metabolic function in both males 
and females because the cellular effects were 
not sex selective. Finally, human studies sug-
gest a connection of diabetes to long-term OP 
exposure (Morgan et al. 1980; Saldana et al. 
2007) and a link between gain-of-function AC 
gene poly  morphisms and diabetes susceptibil-
ity (Nordman et al. 2008). Our results thus 
provide a mechanistic under  pinning for these 
population studies. Nevertheless, it is clear that 
actions on the hepatic AC pathway are likely 
to be just the tip of the iceberg for the meta-
bolic abnormalities wrought by early-life OP 
exposure. In our earlier work, we showed how 
additional stresses imposed by elevated dietary 
fat intake can reveal defects that likely originate 
in adipo  cyte dysfunction rather than in hepatic 
metabolism (Lassiter et al. 2008, 2010), and 
it would be worthwhile to pursue these addi-
tional contributions to prediabetes.
There are similar implications for the 
significant, albeit lesser, effects of DZN and 
PRT exposure on AC signaling in the heart 
and cerebellum. Transgenic animals that 
produce AC hyperstimulation through over-
expression of βARs or Gs show development 
of cardio  myopathies and abnormal heart 
rate regulation (Gao et al. 2003; Iwase et al. 
1996). Alterations in m2AChR expression, 
which we detected for PRT, also have cor-
responding effects on cardiac function and 
the response to autonomic input (LaCroix 
et al. 2008). Importantly, the fact that DZN 
reduced heart weight significantly and to a 
greater extent than body weight indicates the 
need to pursue potential consequences for Developmental diazinon and parathion exposure
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cardiac function, which have been much less 
studied than hepatic function. Indeed, the 
prediabetic changes seen after neo  natal OP 
exposure are themselves likely to contribute 
to further cardio  vascular morbidities. In the 
cerebellum, we found a non  monotonic effect 
of DZN, with enhanced AC signaling at the 
low dose that disappeared or was reversed 
at the high dose; this likely represents the 
positive neuro  trophic effect of acetyl  choline 
produced by a small degree of cholinesterase 
inhibition, offsetting the direct effects of low 
exposure (Timofeeva et al. 2008a). In con-
trast, PRT produced up-regulation with a 
typical, monotonic dose–effect relationship. 
Most important, the disparate dose–effect 
patterns of effects on AC signaling for both 
DZN and PRT correspond to the differences 
in behavioral findings between the two agents 
(Timofeeva et al. 2008a, 2008b).
Our results support the view that develop-
mental exposure to OPs targets the trajectory 
of AC signaling in peripheral tissues, thus 
extending their actions outside the nervous sys-
tem, with the consequences that a) the effects 
on signaling occur with nonsympto  matic 
exposures, and b) effects differ among OPs 
even at toxicodynamically equivalent exposures 
as assessed at the level of brain cholinesterase 
inhibition (Slotkin et al. 2006b). Further, the 
liver appears to be especially sensitive to per-
sistent disruption of AC signaling, involving 
sensitization of the entire pathway via induc-
tion of AC activity. In turn, this provides a 
likely mechanism for the metabolic conse-
quences of neonatal OP exposure identified 
in earlier studies, indicative of a prediabetic 
state (Lassiter et al. 2010; Slotkin et al. 2005). 
Indeed, global sensitization is likely to have 
widespread consequences in general because it 
affects all humoral signals that operate through 
cAMP, rather than involving any single input. 
Future studies will need to address how the 
tissue-selective changes in cell signaling come 
about, that is, whether they involve a direct 
impact of the OPs on expression or function 
of the signaling proteins, whether they are 
downstream events secondary to effects on dif-
ferentiation of hepatocytes and myocytes, or 
whether they originate in upstream effects on 
hormonal or neuronal input. In any case, our 
findings extend the Barker (2003) hypothe-
sis, which originally related pre  natal growth 
restriction to subsequent development of 
cardio  vascular disease and diabetes, to include 
otherwise non  symptomatic chemical expo-
sures that may produce similar outcomes with-
out the precondition of fetal/neonatal growth 
restriction. Our findings point out the need 
to explore the possibility that develop  mental 
exposure to common chemical contaminants 
contributes to the explosive worldwide increase 
in diabetes and obesity.
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